Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mab-3f8 + sargramostim
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Combination of a monoclonal antibody, **3F8** (in murine or humanized form, targets disialoganglioside GD2 on tumor cells), and **sargramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF). This drug regimen is used as an immunotherapy, primarily in high-risk neuroblastoma and also in trials for osteosarcoma. 3F8 exerts antitumor effects primarily via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against GD2-expressing tumor cells. Sargramostim enhances the immune effector function of granulocytes and monocytes, augmenting the ADCC efficacy of 3F8. The combination aims to eradicate minimal residual disease by boosting both direct tumor killing and immune-mediated destruction. Developed and studied predominantly at Memorial Sloan Kettering Cancer Center.
- Brand names
- Leukine
- Other names
- murine monoclonal antibody 3F8 + sargramostimanti-GD2 monoclonal antibody 3F8 + granulocyte-macrophage colony-stimulating factor3F8 + GM-CSF
02
Targets
GD2CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on mab-3f8 + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mab-3f8 + sargramostim.